IP Library Patent Application 17393213
Patent Application
App. No. 17/393,213

METHODS OF TREATING MIXED DYSLIPIDEMIA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/393,213
Abstract

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Claims (11)

1 . A method of treating high triglycerides comprising administering eicosapentaenoic acid (EPA) and a statin to a subject having a baseline LDL-C level of at least 100 mg/dl, a baseline non-HDL-C level of at least 130 mg/dl, and a baseline triglyceride level of at least 250 mg/dl, wherein the EPA is in a capsule in an amount of at least about 95%, by weight, of all fatty acids present in the capsule, the statin and the EPA are co-administered in a same dosage unit, and the EPA is administered to the subject in an amount sufficient to provide a dose of 2500 mg to about 10,000 mg of the EPA per day.

2 . The method of claim 1 comprising administering the statin and the EPA for a period of time to reduce an Apo-B level and the baseline non-HDL-C level in the subject.

3 . The method of claim 1 comprising administering the statin and the EPA for a period of time to reduce an Apo-B level in the subject without increasing the baseline LDL-C level in the subject.

4 . The method of claim 1 comprising administering the statin and the EPA for a period of time to reduce an Apo-B level in the subject compared to a control subject who has a baseline triglyceride level of at least about 250 mg/dl and has received the statin but not the EPA.

5 . The method of claim 1 , wherein the EPA is ethyl-EPA.

6 . The method of claim 1 , wherein the subject has a baseline triglyceride level of at least 500 mg/dl.

7 . The method of claim 1 , wherein the subject has a baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl.

8 . The method of claim 1 , wherein the subject is administered the statin and the EPA for a period of time of at least about 2 years.

9 . The method of claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 15%.

10 . The method of claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 20%.

11 . The method of claim 1 , wherein the statin is selected from lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin and simvastatin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2021
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; MANKU, MEHAR
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 057071/0487 →